Nortopixantrone (BBR-3438), a member of the 9-aza-anthrapyrazole family, is a DNA topoisomerase inhibitor potentially designed for the treatment of gastric cancer, ovarian cancer. BR 3438 exhibited a unique profile of preclinical activity with a superior efficacy against prostatic carcinoma models compared to reference compounds (doxorubicin and losoxantrone). Nortopixantrone had been in phase II clinical trials with Novuspharma for the treatment of gastric cancer, ovarian cancer and prostate cancer. But this research was discontinued in 2002.

Metrenperone, a 5-hydroxytryptamine blocker, is used in veterinary as an antimyopathic agent. Experiments on rabbits have shown that the drug had positive effects on collagen turnover, remodeling, and organization during acute inflammation and fibroplasia.

Iodecimol is nonionic-dimeric contrast medium patented by Schering A.-G. for myocardial imaging

Opaviraline (also known as GW 420867), a nonnucleoside reverse transcriptase inhibitor that was studied for the treatment of HIV infections. The drug participated in clinical trials phase II in Germany, in South Africa, and in the United Kingdom, however, these studies were discontinued.

Olradipine (also known as S 11568) is a L-type Ca(2+) channel antagonist. This drug was being developed in France for the treatment of heart failure, hypertension, and ischemic heart disorder. However, all these studies were discontinued.

Febuverine is a spasmolytic and local anesthetic.

Tuvatidine (HUK 978) is a potent H2-antagonist. HUK 978 was shown to be devoid of activity at the histamine H1-receptor, the muscarinic receptor and the alpha and beta-adrenergic receptors. In both the guinea-pig gastric mucosa preparation and the rat perfused stomach model, HUK 978 was a powerful inhibitor of acid secretion. HUK 978 is a highly specific H2-antagonist and inhibits acid secretion for longer periods than other competitive compounds.

FLUBANILATE is a CNS stimulant.

FLUDOXOPONE is an anticholesterolemic agent.

Eticlopride {2S(−)-3-chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxybenzamide} is an antagonist at dopamine D2 and D3 receptors. It is widely used for in vivo, in vitro, and ex vivo examination of D2/D3 receptors densities and function. Eticlopride exerts antipsychotic activity in animals.